[Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy)].
BACKGROUND
FEC (5-FU+epirubicin+cyclophosphamide) therapy has been used as adjuvant chemotherapy for breast cancer patients with nodes positive. The aim of this study was to evaluate host immunity and side effects of the FEC therapy. The effect of oral administration of Lentinus edodes mycelia (LEM) was also observed.


METHODS
Ten patients were enrolled in this study. The treatment with 5-FU (500 mg/m2), epirubicin (75 mg/m2) and cyclophosphamide (500 mg/m2) was administered every 21 days for 2 cycles, and LEM (9 g/day po) was administered during the 2nd cycle.


RESULTS
NK cell activity and the number of white blood cells decreased on the 7th day after the therapy, and they recovered on the 21st day. However, this NK cell activity and the number of white blood cells didn't decrease when the FEC therapy was used with LEM po.


CONCLUSIONS
FEC 75 therapy has made some impacts on host immunity, and LEM with the FEC 75 therapy might have prevented host immunity.
Nagashima
Yukiko
Y
Dept. of Surgery II, Yamaguchi University School of Medicine.
Sanpei
Noriko
N
Yamamoto
Shigeru
S
Yoshino
Shigehumi
S
Tangoku
Akira
A
Oka
Masaaki
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D015251:Epirubicin / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D005656:Fungal Proteins / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D011134:Polysaccharides / Q000008:administration & dosage
D005656:Fungal Proteins; C061242:Lentinus edodes mycelia extract E-P-LEM; D011134:Polysaccharides; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil